Fullerton Health shareholder spat clouds US$1 billion sale
A BITTER feud among three friends-turned-foes - all shareholders and co-founders of Fullerton Healthcare Corp (Fullerton Health) - could imperil the months-long sale process of the Asian healthcare solutions firm, including last week's sweetened non-binding offer by Beverly-Hills private equity firm Platinum Equity for the Singapore-headquartered firm.
Ties over the past year or so have frayed between David Sin of SIN Capital, which majority-owns Fullerton Health, and his long-time doctor-colleagues-turned pals Michael Tan and Daniel Chan, the firm's minority shareholders and executive directors.
An early sign of the enmity emerged at the end of 2019, when Dr Tan and Dr Chan stepped down as the medical-services firm's chief executive officer (CEO) and deputy CEO respectively. Following a search for an executive CEO, Ho Kuen Loon was appointed Fullerton Health's group CEO in Jan 2020.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
HSBC brings out tax tools for UK businesses ahead of new rules
Nelson Loh intends to plead guilty to charges including forgery and cheating
Singapore shares edge up at Friday’s open; STI up 0.2%
Data leak reveals links between money laundering accused Su Jianfeng and sale of Dubai properties
‘No better player’ than GIC to help revitalise fortunes of Singapore stock market: observers
Businessmen in Singapore placed on China’s wanted list weeks after money laundering raid in 2023